A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms by Carolina Martínez-Laperche, Elena.

Slides:



Advertisements
Similar presentations
Novel Assay for Ex Vivo Evaluation of Antiproliferative Effect of Hypomethylating Agents 5-Azacytidine and Decitabine in AML Patient Samples by Pilar Hernandez,
Advertisements

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability.
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation:
Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell.
Donor CTLA-4 Genotype Influences Clinical Outcome after T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling.
Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms’ Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic.
by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Mismatch on Glutathione S-Transferase T1 Increases the Risk of Graft-versus-Host Disease and Mortality after Allogeneic Stem Cell Transplantation  María.
Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous.
A Novel Diagnostic and Prognostic Biomarker Panel for Endothelial Cell Damage– Related Complications in Allogeneic Transplantation  Shotaro Tatekawa, Akio.
Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk.
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.
How we choose factor VIII to treat hemophilia
Evaluation of published single nucleotide polymorphisms associated with acute GVHD by Jason W. Chien, Xinyi Cindy Zhang, Wenhong Fan, Hongwei Wang, Lue.
by Rocio Gonzalez-Conejero, Maria L
by Kenneth Weinberg, Bruce R. Blazar, John E
Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia by Jose Roman-Gomez, Antonio.
Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.
Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset.
Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies 
Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft.
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative.
Study of Kidney Function Impairment after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. A Single-Center Experience 
Brian Kornblit, Tania Masmas, Søren L. Petersen, Hans O
Comparable survival between HIV+ and HIV− non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation by.
Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,
Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell.
Plasma Biomarkers in Graft-versus-Host Disease: A New Era?
by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka
Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation  Jaime Sanz, Alessandra.
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,
Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study 
Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia by Judith Reina-Castillón, Roser Pujol, Marcos López-Sánchez, Benjamín.
Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective.
Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among.
Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.
Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD  Suzanne van.
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation:
Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia by Jaime Sanz, Mi Kwon, Guiomar Bautista, Miguel.
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.
Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.
Risk Factors for Late Infections after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Related Donor  Marie Robin, Raphaël Porcher,
Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.
A and B, ROC curves of the proteomics panel diagnosis.
A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.
Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS by Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada,
Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.
Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study 
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine- Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic.
Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders  Mi Kwon,
Peripheral Blood Eosinophilia Has a Favorable Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation  Dong.
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.
Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation 
Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches  David Gallardo, Anna Bosch-Vizcaya, Rocío Rodríguez-Romanos,
High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.
Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors by Manabu Wakamatsu, Seitaro Terakura,
Manuel Jurado, Carlos Vallejo, José A
ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.
Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria  Madan Jagasia, Jennifer Giglia, Wichai.
Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.
Prospective Study of the Incidence, Clinical Features, and Outcome of Symptomatic Upper and Lower Respiratory Tract Infections by Respiratory Viruses.
Impact of age on clinical risk scores in follicular lymphoma
The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib by Chung H. Kok, David T.
External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation by Roni Shouval, Joshua A. Fein,
Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease by Paula Rodriguez-Otero,
Presentation transcript:

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms by Carolina Martínez-Laperche, Elena Buces, M. Carmen Aguilera-Morillo, Antoni Picornell, Milagros González-Rivera, Rosa Lillo, Nazly Santos, Beatriz Martín-Antonio, Vicent Guillem, José B. Nieto, Marcos González, Rafael de la Cámara, Salut Brunet, Antonio Jiménez-Velasco, Ildefonso Espigado, Carlos Vallejo, Antonia Sampol, José María Bellón, David Serrano, Mi Kwon, Jorge Gayoso, Pascual Balsalobre, Álvaro Urbano-Izpizua, Carlos Solano, David Gallardo, José Luis Díez-Martín, Juan Romo, and Ismael Buño BloodAdv Volume 2(14):1719-1737 July 24, 2018 © 2018 by The American Society of Hematology

Carolina Martínez-Laperche et al. Blood Adv 2018;2:1719-1737 © 2018 by The American Society of Hematology

Box plots of CCRs for patients who develop (CCR1) and do not develop (CCR0) GVHD/NRM as predicted with the different models. Box plots of CCRs for patients who develop (CCR1) and do not develop (CCR0) GVHD/NRM as predicted with the different models. The AUC and the number of variables used are shown in each case. The predictive ability of each model, built using 85% of the samples (training set), was computed with the remaining 15% of the samples (test set). To evaluate the performance and predictive ability of each model, training and testing samples were randomly selected and the procedure repeated 100 times. The distribution of the CCR and AUC over the 100 iterations is shown by means of box plots. CCRs for the development of aGVHD, cGVHD, and NRM obtained using the predictive model including only clinical variables (upper panels), the model including only genetic variables (middle panels), and the model including both clinical and genetic variables (lower panels) are shown. Number of clinical/recipient SNPs/donor SNPs variables is indicated in parenthesis. Carolina Martínez-Laperche et al. Blood Adv 2018;2:1719-1737 © 2018 by The American Society of Hematology

Stratification of the whole cohort of patients (n = 263) according to the risk of developing acute GVHD. Risk was calculated using the proposed predictive model including clinical variables (upper panels), genetic variables (middle panels), or both clinical and genetic variables (lower panels). Stratification of the whole cohort of patients (n = 263) according to the risk of developing acute GVHD. Risk was calculated using the proposed predictive model including clinical variables (upper panels), genetic variables (middle panels), or both clinical and genetic variables (lower panels). Cumulative incidence curves are shown for the development of grade 2 to 4 aGVHD (left panels) and grade 3 to 4 aGVHD (right panels). The cutoff used was 0.28 for grade 2 to 4 aGVHD and 0.11 for grade 3 to 4 aGVHD. Carolina Martínez-Laperche et al. Blood Adv 2018;2:1719-1737 © 2018 by The American Society of Hematology

Stratification of the whole cohort of patients (n = 201) according to the risk of developing chronic GVHD. Risk was calculated using the proposed predictive model including clinical variables (upper panels), genetic variables (middle panels), or both clinical and genetic variables (lower panels). Stratification of the whole cohort of patients (n = 201) according to the risk of developing chronic GVHD. Risk was calculated using the proposed predictive model including clinical variables (upper panels), genetic variables (middle panels), or both clinical and genetic variables (lower panels). Because the time of onset after transplantation was not available to build cumulative incidence curves, bar charts are shown for cGVHD (right panels) and extensive cGVHD (left panels). The cutoff used was 0.53 for cGVHD and 0.3 for extensive cGVHD. Carolina Martínez-Laperche et al. Blood Adv 2018;2:1719-1737 © 2018 by The American Society of Hematology